放疗联合双侧髂内动脉灌注化疗治疗晚期宫颈癌

Analysis of curative effect of radiotherapy combined with bilateral internal iliac arterial infusion chemotherapy on advanced cervical cancer

目的：分析放疗联合双侧髂内动脉灌注化疗治疗晚期宫颈癌的疗效。方法以解放军第一五二中心医院2012年1月至2013年12月收治的50例晚期宫颈癌患者为研究对象，随机将其分为两组，对照组患者给予单纯放疗治疗，观察组患者在对照组基础上联合双侧髂内动脉灌注化疗治疗，治疗后随访1年，比较两组临床疗效、不良反应及随访结果。结果观察组治疗有效率为84.0％，对照组为56.0％，两组比较差异有统计学意义（P＜0.05）。观察组1年复发率、转移率分别为24.0％、16.0％，对照组为52.0％、44.0％，两组比较差异有统计学意义（P＜0.05），两组1年生存率比较差异未见统计学意义（P＞0.05）。观察组不良反应主要表现为骨髓抑制及消化道反应，对照组不良反应主要为迟发性泌尿系损伤及肠道损伤。结论放疗联合双侧髂内动脉灌注化疗治疗晚期宫颈癌临床疗效明确，能有效提高1年生存率，显著降低1年复发率，值得临床推广。

Objective To analyze the effects of radiotherapy combined with bilateral internal iliac arterial infusion chemotherapy on advanced cervical cancer. Methods Fifty patients with advanced cervical cancer from January 2012 to December 2013 were selected as the research objects. They were randomly divided into two groups, the control group was only given radiotherapy treatment, the observation group were given bilateral internal iliae artery infusion chemotherapy treatment based on the control group, followed-up 1 year after treatment, and then compared the clinical efficacy, adverse reactions and the follow-up results of two groups. Results The effective rate in the observation group was 84%, and 56% in the control group, the difference was significant（ P 〈 0. 05 ）. The 1 year recurrence rate, metastasis rate of observation group were 24% , 16% , and 52% , 44% of the control group, the differences were statistical significance （P 〈0.05）. Between two groups, 1 year survival rate showed no significant difference （ P 〉 0. 05）. In addition, the main side effects of observation group were myelosuppression and gastrointestinal tract reaction, major adverse reactions in control group were delayed injury and intestinal injury of urinary system. Conclusions The effect of radiotherapy combined with bilateral in- ternal iliac arterial infusion chemotherapy on advanced cervical cancer is definite, can effectively improve the survival rate of 1 year, significantly reduce the recurrence rate in 1 year, is worth clinical promotion.